Krakow Center for Medical Research and Technology, John Paul II Hospital, Kraków, Poland.
Department of Trauma and Orthopedics, St. Luke's Regional Hospital in Tarnów, Tarnów, Poland.
Thromb Haemost. 2018 Apr;118(4):654-663. doi: 10.1055/s-0038-1636535. Epub 2018 Apr 4.
Prothrombotic clot phenotype may characterize patients developing deep vein thrombosis (DVT) despite pharmacological thromboprophylaxis. We studied the role of fibrin clot properties and its potential determinants in individuals who experienced DVT after lower limb injury.
In a case-control study, we assessed 50 patients who developed DVT despite prophylactic use of low-molecular-weight heparins (the failed thromboprophylaxis group) after a lower limb injury, and three age- and sex-matched control groups, 50 patients each: (1) patients with trauma-related DVT without prior thromboprophylaxis; (2) individuals with unprovoked DVT; (3) patients without history of DVT (the no-DVT controls). Fibrin clot properties, along with thrombin concentration and α-antiplasmin, were assessed following 3 months of anticoagulation in all DVT patients.
Compared with the no-DVT controls, the failed thromboprophylaxis group exhibited denser fibrin networks (12.8% lower clot permeability [K], = 0.0008) and impaired fibrinolysis (46.2% longer clot lysis time [CLT], = 0.0001 and 8% lower rate of D-dimer release from clots, = 0.0008). In the unprovoked DVT, similar K and 14.9% shorter CLT ( = 0.02) were reported compared with the failed thromboprophylaxis group. The failed thromboprophylaxis patients had higher odds of having elevated peak thrombin generation (>241.5 nM, 90th percentile in the no-DVT controls; odds ratio [OR]: 3.62; 95% confidence interval [CI], 1.86-7.06; = 0.002), and higher odds of having elevated α-antiplasmin (>115.05%; OR: 3.38; 95% CI, 1.64-6.98; = 0.001).
Patients who experienced DVT despite thromboprophylaxis following lower limb trauma display a strongly prothrombotic fibrin clot phenotype, including increased clot density and hypofibrinolysis associated with higher plasma α-antiplasmin.
尽管进行了药物性血栓预防,但血栓前状态的患者仍可能发生深静脉血栓(DVT)。我们研究了下肢损伤后继发 DVT 的患者中纤维蛋白凝块特性及其潜在决定因素的作用。
在一项病例对照研究中,我们评估了 50 例下肢损伤后尽管使用低分子量肝素进行预防性治疗仍发生 DVT 的患者(血栓预防失败组),并将其与 3 个年龄和性别匹配的对照组(每组 50 例)进行比较:(1)无血栓预防的创伤相关 DVT 患者;(2)无诱因性 DVT 患者;(3)无 DVT 病史的患者(无 DVT 对照组)。所有 DVT 患者在抗凝治疗 3 个月后评估纤维蛋白凝块特性、凝血酶浓度和 α2-抗纤溶酶。
与无 DVT 对照组相比,血栓预防失败组的纤维蛋白网络更为致密(纤维蛋白凝胶的通透性降低 12.8%,K 值=0.0008),纤溶能力受损(纤维蛋白凝胶的溶解时间延长 46.2%,CLT 值=0.0001;纤维蛋白凝胶从血栓中释放 D-二聚体的速度降低 8%,D 值=0.0008)。与血栓预防失败组相比,无诱因性 DVT 患者的 K 值更低,CLT 更短(分别为 14.9%,CLT 值=0.02)。血栓预防失败组患者发生高峰值凝血酶生成(>241.5nM,无 DVT 对照组 90 百分位数;比值比 [OR]:3.62;95%置信区间 [CI]:1.86-7.06;=0.002)和高 α2-抗纤溶酶水平(>115.05%;OR:3.38;95%CI:1.64-6.98;=0.001)的可能性更大。
下肢损伤后继发 DVT 且进行了血栓预防的患者存在明显的血栓前纤维蛋白凝块表型,包括纤维蛋白凝块密度增加、纤溶能力降低,与血浆 α2-抗纤溶酶水平升高相关。